Goodwin Advises Kelun Biotech and Harbour BioMed on License Agreement With Windward Bio for an Anti-TSLP Fully Human Antibody for Immunological Diseases for Up to $970 Million Upfront and in Milestone Payments
January 14, 2025
January 14, 2025
BOSTON, Massachusetts, Jan. 14 -- Goodwin, a law firm, issued the following news release:
The Life Sciences team advised Sichuan Kelun Biotech BioPharmaceutical ("Kelun-Biotech") and Harbour BioMed and in a license agreement with Windward Bio AG ("Windward Bio") for HBM9378/SKB378, an anti-thymic stromal lymphopoietin (TSLP) fully human monoclonal antibody co-developed by Kelun-Biotech and Harbour BioMed. Under the terms of the agreement, Windward Bio is granted . . .
The Life Sciences team advised Sichuan Kelun Biotech BioPharmaceutical ("Kelun-Biotech") and Harbour BioMed and in a license agreement with Windward Bio AG ("Windward Bio") for HBM9378/SKB378, an anti-thymic stromal lymphopoietin (TSLP) fully human monoclonal antibody co-developed by Kelun-Biotech and Harbour BioMed. Under the terms of the agreement, Windward Bio is granted . . .